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frequent outpatient Visits 
prevent exacerbation of chronic 
obstructive pulmonary Disease
Hye Jung park  1, Min Kwang Byun1*, taehee Kim1, chin Kook Rhee  2, Kyungjoo Kim2, 
Bo Yeon Kim3, Sang in Ahn4, Yon U Jo5 & Kwang-Ha Yoo6
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory airway disease requiring 
frequent outpatient visits and lifelong management. We aimed to evaluate the roles of frequent 
outpatient visits in prognosis of copD. We used claims data in the national medical insurance review 
system provided by the Health Insurance Review and Assessment Service of Korea from May 1, 2014 to 
April 30, 2015. A definition of COPD was used based on the diagnosis code and medication. Frequent 
visitors were defined as subjects who visited the outpatient clinic for COPD three or more times per 
year. Among 159,025 subjects, 117,483 (73.9%) were classified as frequent visitors. Frequent visitors 
underwent pulmonary function tests and used various inhalers more often than did infrequent visitors. 
the rates of copD exacerbation requiring admission to a general ward, emergency room, or intensive 
care unit were significantly lower in frequent visitors than in infrequent visitors. In multivariable 
analysis, frequent visits were identified as an independent factor preventing COPD exacerbation that 
required admission to a ward (odds ratio [OR], 0.387), emergency room, (OR, 0.558), or intensive care 
unit (OR, 0.39) (all P < 0.001). In conclusion, we showed frequent outpatient visits reduce the risk of 
COPD exacerbation by 45–60%.
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease of the airways that requires 
lifelong management1. A report from the Global Initiative for Chronic Obstructive Lung Disease have described 
routine patient follow-up as essential2. Lung function may worsen over time because of the natural history of 
COPD, so regular visits are needed to ensure frequent pulmonary function tests3. Symptoms and history of exac-
erbations should be monitored at these visits to adjust treatment, identify complications or comorbidities, and 
prevent acute exacerbations4,5. Frequent outpatient visits also offer patients an opportunity to improve their skills 
using inhalers, increase their knowledge of rehabilitation and nutritional support, and receive vaccination, all 
of which improve the clinical outcomes of COPD6–9. However, although there is good reason to believe that fre-
quent outpatient visits have a prognostic benefit in COPD, there is insufficient scientific evidence to support this 
assumption.
Until now, whether or not frequent outpatient visits have a prognostic benefit in COPD and how often patients 
should visit a hospital outpatient clinic to prevent exacerbations has never been investigated. The aim of this study 
was to determine whether or not frequent outpatient visits reduce the risk of exacerbation of COPD using data 
from a Korean national cohort study.
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Methods
ethics statement. The study was approved by the National Evidence-Based Healthcare Collaborating 
Agency Ethics Committee. The need for informed consent was waived by the institutional review board of 
Gangnam Severance Hospital, Yonsei University Health System (approval number 3-2018-0337). All aspects of 
the study were performed in accordance with relevant guidelines and regulations.
Data sources. South Korea has adopted a single mandatory government-established health care insurance 
system, and the Health Insurance Review and Assessment Service (HIRA) is the agency that evaluates all medical 
claims data in South Korea. The HIRA has now accumulated all medical records in South Korea and covers the 
country’s entire population (>50 million)10. The HIRA data have been extensively described in previous stud-
ies11,12. In this study, we retrospectively analysed the data registered in the HIRA database between May 1, 2014 
and April 30, 2015.
Study population. Patients with COPD were defined as those who met the criteria used in a previous 
report that included HIRA data13. This definition is concordant with that used by the HIRA in its COPD quality 
evaluation program. The criteria used were as follows: age ≥40 years; ICD-10 codes for COPD or emphysema 
(J43.0×-J44.x, except for J43.0 as primary or secondary [within fourth position’ diagnosis]); and use of more than 
one COPD medication at least twice a year.
Definition of terms. Frequent visitors were defined as those who visited a hospital outpatient clinic for 
follow-up of COPD three or more times per year regardless of the interval between visits and the site, and others 
were classified as infrequent visitors. The Charlson Comorbidity Index (CCI), which facilitates prediction of the 
prognosis and mortality, was calculated as previously described14,15. Exacerbation of COPD requiring hospital 
admission was defined as an admission to a general ward, emergency room (ER), or intensive care unit (ICU) 
with a diagnosis of COPD as the principal or first additional diagnosis.
Statistical analysis. The t-test and chi-square test were used to identify differences in continuous and cat-
egorical variables, respectively, between frequent and infrequent visitors. Univariable and multivariable logistic 
regression analyses were used to identify significant risk factors for exacerbation of COPD. A cumulative risk 
ratio graph was drawn using the Kaplan-Meier method. A Cox regression model was used to identify significant 
risk factors for exacerbation of COPD over time with adjustment for various factors. All statistical analyses were 
performed using SPSS for Windows (version 18.0; IBM Corp., Armonk, NY). A P-value <0.05 was considered 
statistically significant.
Results
Subject demographics. We classified the 159,025 patients with COPD registered in the HIRA as infrequent 
visitors (n = 41,542) or frequent visitors (n = 117,483). The frequent visitor group was significantly older and 
included more male patients. Frequent visitors were more likely than infrequent visitors to visit a primary care 
facility for follow-up. Frequent visitors had more comorbidity in the form of osteoporosis, depressive disorder, 
arthritis, diabetes mellitus, hypertension, and allergic rhinitis, whereas pneumothorax and congestive heart fail-
ure was more common in infrequent visitors. However, there was no significant between-group difference in the 
CCI value. The proportion of patients admitted with an exacerbation of COPD in the previous year was signifi-
cantly higher in the frequent visitor group than in the infrequent visitor group (9.2% vs 7.2%, P < 0.001; Table 1).
test performed, medications prescribed, and health care utilization. Radiographic and computed 
tomography examinations were performed less often in frequent visitors than in infrequent visitors. However, fre-
quent visitors underwent pulmonary function tests more often than did infrequent visitors. All medications were 
prescribed more often for frequent visitors than for infrequent visitors The mean number of outpatient visits was 
significantly higher in the frequent visitor group than in the infrequent visitor group (6.81 ± 6.21 vs 1.74 ± 0.59, 
P < 0.001). The mean number of inpatient visits was significantly lower in the frequent visitor group than in the 
infrequent visitor group (0.20 ± 0.73 vs 0.43 ± 1.01, P < 0.001), as was the proportion of subjects ever admitted to 
a general ward (11.8% vs 23.8%, P < 0.001). The mean numbers of ER and ICU admissions were also significantly 
lower in the frequent visitor group than in the infrequent visitor group. Furthermore, the percentages of subjects 
ever admitted to an ER or ICU were significantly lower in the frequent visitor group than in the infrequent visitor 
group. (Table 2).
Significant risk factors for exacerbation of COPD requiring admission to a general ward. Older 
age, female sex, having medical aid insurance, attending a low-grade care facility, a high CCI, and admission with 
an exacerbation of COPD in the previous year were significant risk factors for an inpatient admission in the uni-
variable and multivariable analyses. Frequent visiting was a protective factor in univariable analysis (odds ratio 
[OR] 0.428; 95% confidence interval [CI] 0.416–0.441; P < 0.001). After adjustment for the above-mentioned 
confounding factors, frequent visiting significantly reduced the likelihood of a COPD exacerbation requiring 
admission to a general ward (OR 0.294; 95% CI 0.284–0.304; P < 0.001, Table 3).
The Kaplan-Meier graph showed a significant difference in the risk of admission over time between the fre-
quent visitor group and the infrequent visitor group (OR 0.464; 95% CI 0.453–0.477; P < 0.001; Fig. 1A). Cox 
regression analysis showed a significant reduction in the risk of COPD exacerbation requiring admission to a 
general ward in the frequent visitor group after adjustment for the confounding factors (OR 0.387; 95% CI 0.377–
0.397; P < 0.001, Table 4).
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Significant risk factors for exacerbation of copD requiring admission to an emergency 
room. The risk factors for exacerbation of COPD requiring admission to an ER were similar to those for inpa-
tient admission. Frequent visitors had a significantly lower ER admission rate in univariable analysis (OR 0.663; 
95% CI 0.638–0–690; P < 0.001) and multivariable analysis (OR 0.515; 95% CI 0.493–0.538; P < 0.001; Table 3).
The Kaplan-Meier graph and Cox regression analysis identified frequent visiting as significantly protective 
against exacerbation of COPD requiring ER admission after adjustment for the above factors (OR 0.676; 95% CI 
0.651–0.702; P < 0.001, Fig. 1B) (OR 0.558; 95% CI 0.537–0.579; P < 0.001, Table 4).
Significant risk factors for exacerbation of COPD requiring admission to an ICU. The risk factors 
for exacerbation of COPD requiring admission to an ICU were also similar to those for inpatient admission The 
ICU admission rate was significantly lower in the frequent visitor group in univariable analysis (OR 0.449; 95% CI 
0.419–0.481; P < 0.001) and multivariable analysis (OR 0.370; 95% CI 0.343–0.398; P < 0.001, Table 3).
The Kaplan-Meier graph and Cox regression analysis showed that the risk of an ICU admission over time 
was significantly lower in the frequent visitor group than in the infrequent visitor group (OR 0.453; 95% CI 
0.423–0.485; P < 0.001, Fig. 1C) (OR 0.391; 95% CI 0.365–0.420; P < 0.001, Table 4).
Discussion
The results of this study show that frequent outpatient visits (three or more times per year) for management of 
COPD can reduce the risk of an exacerbation requiring admission by 45–60%. The rate of reduction in exacerba-
tion of COPD achieved in the present study is much higher than that reportedly achieved by use of inhalers which 
is well-known important treatment modality in COPD (15–30%)16,17. COPD is a chronic disease that requires 
patients to understand the nature of their condition, to cooperate with their doctors, and to manage their disease 
lifelong. Frequent outpatient visits offer the opportunity for patients to have their lung function and symptom 
control checked, to improve their skills in using inhalers, and to have their treatment adjusted to prevent acute 
exacerbation. This study confirmed that frequent visitors had more frequent pulmonary function tests and were 
prescribed COPD medications, mainly inhalers, more often compared with infrequent visitors. Frequent checks 
of disease status and early upstaging of COPD medication might have influenced the prognosis of the patients in 
our study. Frequent visits can also reflect good adherence to treatment. With these various effects, simply making 
frequent outpatient visits can greatly improve the prognosis of COPD.
However, frequent outpatient visits could mean not only “good adherence” but also “severe COPD”. The 
severity of COPD is strongly associated with exacerbation during the previous year, symptom score, and airflow 
obstruction as confirmed by PFT18,19. Due to the inevitable limitation of national big data, symptom score and 
the results of PFT could not be obtained. In this study, “admission with exacerbated COPD in the previous year” 






Age, years (mean and SD) 70.8 ± 10.9 71.1 ± 9.9 <0.001
Male sex, % 64.6 74.8 <0.001
With medical aid 
insurance, % 12.7 16.0 <0.001
Type of hospital, %
Primary care 60.0 70.0 <0.001
Secondary 15.4 11.9 <0.001
Tertiary 31.9 29.6 <0.001
Comorbidity, %
Ischemic heart disease 1.5 1.6 0.449
Osteoporosis 2.3 2.7 <0.001
Depressive disorder 1.0 1.6 <0.001
Arthritis 0.5 0.9 <0.001
Diabetes mellitus 8.5 9.2 <0.001
Pneumothorax 0.9 0.8 <0.001
Congestive heart failure 5.6 4.8 <0.001
Hypertension 15.8 22.1 <0.001
Anaemia 1.8 1.7 0.431
Allergic rhinitis 27.6 38.4 <0.001
CCI (mean and SD) 1.4 ± 0.8 1.2 ± 0.8 0.846
Admission with 
exacerbated COPD in 
previous year, %
7.2 9.2 <0.001
Total number of subjects 41,542 117,483
Table 1. Demographics of patients attending frequently and infrequently for management of chronic 
obstructive pulmonary disease. CCI, Charlson Comorbidity Index; COPD, chronic obstructive pulmonary 
disease; CT, computed tomography; SD, standard deviation Presented as bold in statistically insignificant value.
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of COPD. Although this substitution and adjustment is not perfect, the effectiveness of “frequent visit” can be 
approximated to the effectiveness of “good adherence” in multivariable analysis.
The type of hospital was one of the important factors in the exacerbation of COPD in this study. The propor-
tion of general healthcare providers, specialists of internal medicine, and sub-specialists in pulmonology might 
vary according to the type of hospital. Therefore, the quality of care can vary according to the type of hospi-
tal. A recent study showed that the prescription rate of inhaled bronchodilator, which is a fundamental drug of 
choice for COPD, was 92.6% and 40.5% in tertiary hospitals and private clinics, respectively20. Therefore, we also 
adjusted this factor, ‘type of hospital’, to reduce the confounding factor in Tables 3, 4.
Until now, there have been no studies of the benefits of frequent outpatient visits in terms of the prognosis 
and how often patients should visit an outpatient clinic. The findings of a study by Bischoff et al. on routine 
monitoring of COPD in general practice were negative21. However, in that study, the frequency of monitoring 
was determined by general practitioners, and 20% of patients attended for routine monitoring only once a year21. 
Therefore, it is probable that this relatively low frequency of outpatient visits accounts for the negative results. 
Einarsdottir et al. showed that regular primary care visits can prevent hospitalization and mortality in patients 
with COPD22. However, they did not concentrate on the ‘frequency’ of clinical visits; instead, they focused on the 
effects of ‘regularity’. Moreover, only older individuals (aged ≥ 65 years), who had a variety of chronic respiratory 
diseases including asthma, were enrolled in that study. In addition, we have previously reported on the benefits 
of frequent outpatient visits by patients with ‘asthma’ but not COPD12. Indeed, the significant contribution of 
frequent hospital visits to the prognosis of COPD has been demonstrated for the first time in the present study.
Uncontrolled symptoms and a history of exacerbation in the previous year can prompt patients to visit an 
outpatient clinic more frequently. In this study, most of the medications were more predominantly prescribed to 
the frequent visitors compared to infrequent visitors. It can mean that frequent visitors have severe symptoms or 
‘good adherence’. In addition, exacerbation of COPD in the previous year was also more prevalent in frequent vis-
itors than in infrequent visitors (9.2% vs. 7.2%). We can assume that the frequent visitors represent a more severe 
status of COPD compared to infrequent visitors. Although frequent visitors have severe COPD, the exacerbation 
rate in frequent visitors was similar in the following year (11.8%) to that in the previous year (9.2%); however, 







Chest radiography 14.0 13.1 <0.001
Chest CT scan 1.2 0.6 <0.001
Pulmonary function tests 33.2 45.7 <0.001
Prescribed medication, %
Systemic beta-agonist 26.0 29.9 <0.001
Theophylline 56.9 66.0 <0.001
LABA 6.3 10.5 <0.001
LAMA 30.6 50.1 <0.001
LABA/LAMA 0.0 0.1 0.008
SABA 29.2 31.1 <0.001
SAMA 13.5 10.6 <0.001
ICS 12.6 15.0 <0.001
ICS/LABA 29.1 43.9 <0.001
PDE-4 inhibitors 1.0 3.3 <0.001
Medical service utilization
[Outpatient visit]
  Mean number of outpatient visits 1.74 ± 0.59 6.81 ± 6.21 <0.001
  Outpatient visit, % 92.1 100.0 <0.001
[Inpatient admission]
  Mean number of admissions 0.43 ± 1.02 0.20 ± 0.73 <0.001
  Admission to a general ward, % 23.8 11.8 <0.001
[ER admission]
  Mean number of admissions 0.13 ± 0.44 0.10 ± 0.59 <0.001
  Admission to ER, % 10.0 6.9 0.001
[ICU admission]
 Mean number of admissions 0.05 ± 0.29 0.02 ± 0.17 <0.001
 Admission to ICU, % 3.5 1.6 <0.001
Table 2. Health care utilization and medications prescribed according to study group. ER, emergency room; 
ICS, inhaled corticosteroid; ICU, intensive care unit; LABA, long-acting beta-2 agonist; LAMA, long-acting 
muscarinic antagonist; PDE-4, phosphodiesterase-4; SABA, short-acting beta-2 agonist; SAMA, short-acting 
muscarinic antagonist; SD, standard deviation. Presented as bold in statistically insignificant value.
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Therefore, we can infer that infrequent visitors are at risk of exacerbation of COPD even if they have rarely expe-
rienced an exacerbation in the previous year.
Multiple comorbidities can also encourage patients to visit an outpatient clinic frequently. However, in this 
study, we found that the type of comorbidity tended to differ between the two study groups. Most comorbidi-
ties were more prevalent in frequent visitors than in infrequent visitors. However, congestive heart failure and 
pneumothorax was more prevalent in infrequent visitors than in frequent visitors. The CCI was slightly higher 
in infrequent visitors than in frequent visitors, but the difference was not statistically significant. Further studies 
concerning the relationship between comorbidity and hospital visits are needed.
We chose three visits as the cut-off number of outpatient clinic visits per year to classify subjects as frequent or 
infrequent visitors with following reasons. First, we considered that one or two outpatient visits per year would be 
too few, considering the negative results in a previous study21. Second, another study demonstrated that a cut-off 
value of three was significant in asthma, which is another representative chronic respiratory disease12. Last, in 
Korea, a COPD quality evaluation program was launched in 2014 to improve the quality of the management pro-
tocol implemented by all hospitals in Korea; and that includes frequent outpatient visits (three times or more per 
year) as an important parameter. We wanted to know whether this parameter is really needed.
The effect of frequent visits on the admission rate for exacerbation of COPD depended on the admission 
route. In frequent visitors, the rate of admission to a general ward or ICU decreased by 61% but by only 44% for 
Parameter
Univariable analysis Multivariable analysis
OR (95% CI) P-value OR (95% CI) P-value
COPD exacerbation requiring general ward admission
Age 1.027 (1.026–1.029) <0.001 1.019 (1.017–1.020) <0.001
Male sex 0.896 (0.869–0.923) <0.001 0.760 (0.733–0.788) <0.001
Medical aid insurance 1.438 (1.388–1.490) <0.001 1.159 (1.111–1.209) <0.001
Type of hospital
  Primary care 2.592 (2.502–2.685) <0.001 11.992 (11.306–12.720) <0.001
  Secondary 3.870 (3.744–4.000) <0.001 13.182 (12.479–13.926) <0.001
  Tertiary 0.406 (0.391–0.421) <0.001 1.73 (1.649–1.814) <0.001
CCI 2.095 (2.064–2.126) <0.001 1.931 (1.900–1.963) <0.001
Admission with exacerbated 
COPD in previous year 5.819 (5.607–6.039) <0.001 4.659(4.463–4.864) <0.001
Frequent visitor 0.428 (0.416–0.441) <0.001 0.294(0.284–0.304) <0.001
COPD exacerbation requiring ER admission
Age 1.030 (1.028–1.032) <0.001 1.023 (1.021–1.025) <0.001
Male sex 1.206 (1.155–1.258) <0.001 0.97 (0.928–1.020) 0.250
Medical aid insurance 1.403 (1.339–1.471) <0.001 1.175 (1.116–1.237) <0.001
Type of hospital
  Primary care 11.824 (10.833–12.906) <0.001 24.448 (22.179–26.948) <0.001
Secondary 1.471 (1.400–1.545) <0.001 3.400 (3.194–3.612) <0.001
  Tertiary 0.411 (0.391–0.432) <0.001 1.713 (1.617–1.816) <0.001
CCI 1.795 (1.766–1.825) <0.001 1.592 (1.563–1.621) <0.001
Admission with exacerbated 
COPD in previous year 4.730 (4.523–4.946) <0.001 3.313 (3.15503.479) <0.001
Frequent visitor 0.663 (0.638–0.690) <0.001 0.515 (0.493–0.538) <0.001
COPD exacerbation requiring ICU admission
Age 1.041 (1.037–1.045) <0.001 1.033 (1.029–1.037) <0.001
Male sex 1.045 (0.967–1.129) 0.268 0.872 (0.804–0.947) 0.001
Medical aid insurance 1.274 (1.165–1.392) <0.001 1.028 (0.936–1.130) 0.558
Type of hospital
  Primary care 35.315 (26.394–47.253) <0.001 54.603 (40.478–73.656) <0.001
  Secondary 1.201 (1.090–1.323) <0.001 2.093 (1.880–2.329) <0.001
  Tertiary 0.363 (0.329–0.401) <0.001 1.464 (1.315–1.629) <0.001
 CCI 1.916 (1.868–1.964) <0.001 1.687 (1.642–1.734) <0.001
Admission with exacerbated 
COPD in previous year 4.383 (4.054–4.737) <0.001 2.840 (2.614–3.08) <0.001
Frequent visitor 0.449 (0.419–0.481) <0.001 0.370 (0.343–0.398) <0.001
Table 3. Significant risk factors for exacerbation of chronic obstructive pulmonary disease in a logistic 
regression model. CCI, Charlson Comorbidity Index; CI, confidence interval; COPD, chronic obstructive 
pulmonary disease; ER, emergency room; ICU, intensive care unit; OR, odds ratio. Presented as bold in 
statistically insignificant value.
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Figure 1. Kaplan-Meier graph showing the cumulative risk of admission to a general ward (a), ER (b), or ICU 
(C) over time. ER, emergency room; ICU, intensive care unit.
Parameter
Univariable analysis Multivariable analysis
OR (95% CI) P-value OR (95% CI) P-value
COPD exacerbation requiring general ward admission
Age 1.025 (1.024–1.026) <0.001 1.014 (1.013–1.015) <0.001
Male sex 0.906 (0.881–0.932) <0.001 0.834 (0.810–0.858) <0.001
Medical aid insurance 1.407 (1.362–1.453) <0.001 1.147 (1.110–1.185) <0.001
Type of hospital
  Primary care 2.434 (2.354–2.517) <0.001 4.84 (4.650–5.038) <0.001
  Secondary 3.303 (3.212–3.396) <0.001 4.921 (4.767–5.081) <0.001
  Tertiary 0.428 (0.414–0.443) <0.001 1.252 (1.206–1.300) <0.001
CCI 1.756 (1.739–1.772) <0.001 1.518 (1.503–1.533) <0.001
Admission with exacerbated 
COPD in previous year 4.764 (4.627–4.905) <0.001 3.193 (3.098–3.291) <0.001
Frequent visitor 0.464 (0.453–0.477) <0.001 0.387 (0.377–0.397) <0.001
COPD exacerbation requiring ER admission
Age 1.028 (1.026–1.030) <0.001 1.021 (1.019–1.023) <0.001
Male sex 1.198 (1.150–1.249) <0.001 0.982 (0.942–1.024) 0.398
Medical aid insurance 1.387 (1.326–1.450) <0.001 1.153 (1.102–1.207) <0.001
Type of hospital
  Primary care 11.189 (10.259–12.204) <0.001 18.308 (16.694–20.079) <0.001
  Secondary 1.448 (1.382–1.518) <0.001 2.577 (2.453–2.708) <0.001
  Tertiary 0.422 (0.402–0.443) <0.001 1.522 (1.475–1.632) <0.001
CCI 1.664 (1.642–1.685) <0.001 1.442 (1.422–1.462) <0.001
Admission with exacerbated 
COPD in previous year 4.325 (4.155–4.502) <0.001 2.831 (2.717–2.951) <0.001
Frequent visitor 0.676 (0.651–0.702) <0.001 0.558 (0.537–0.579) <0.001
COPD exacerbation requiring ICU admission
Age 1.041 (1.037–1.044) <0.001 1.031 (1.027–1.035) <0.001
Male sex 1.044 (0.967–1.127) 0.276 0.871 (0.806–0.942) 0.001
Medical aid insurance 1.270 (1.163–1.387) <0.001 1.039 (0.951–1.136) 0.399
Type of hospital
  Primary care 34.789 (26.005–46.540) <0.001 49.947 (37.081–67.278) <0.001
  Secondary 1.198 (1.089–1.319) <0.001 1.916 (1.735–2.117) <0.001
  Tertiary 0.366 (0.332–0.404) <0.001 1.432 (1.294–1.584) <0.001
CCI 1.831 (1.791–1.871) <0.001 1.568 (1.533–1.603) <0.001
Admission with exacerbated 
COPD in previous year 4.284 (3.971–4.621) <0.001 2.658 (2.457–2.876) <0.001
Frequent visitor 0.453 (0.423–0.485) <0.001 0.391 (0.365–0.420) <0.001
Table 4. Significant risk factors for exacerbation of chronic obstructive pulmonary disease over time in a Cox 
regression model. CCI, Charlson Comorbidity Index; CI, confidence interval; COPD, chronic obstructive 
pulmonary disease; ER, emergency room; ICU, intensive care unit; OR, odds ratio. Presented as bold in 
statistically insignificant value.
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admission to an ER. Acute exacerbation of COPD cannot be entirely prevented. Respiratory infection, a change 
in climate, increased presence of dust particles, and exposure to noxious gases can exacerbate COPD regardless of 
whether or not treatment and management is adequate23. These factors can affect the likelihood of an ER admis-
sion because of their unexpected and sudden nature. An ER admission is usually determined by environmental 
factors rather than the degree of disease control. A previous study also showed that frequent visits reduced the 
risk of an ER admission to a similar extent12. We suggest that the positive effects of frequent visits on unexpected 
and sudden events are relatively weak and led to frequent ER admissions.
COPD is highly prevalent and a major cause of death worldwide24. However, only a small number (2–3%) 
of patients with COPD are diagnosed to have this condition by doctors in clinics in Korea25, as shown in 
world-wide26. COPD needs sustained follow-up, so primary care has a significant role in its management. This 
study showed that only 60–70% of patients with COPD visit for primary care, in contrast with patients with 
asthma, 82% of whom were reported to be reliant on primary care22. This suggests that patients with COPD in 
Korea are more likely to visit a hospital when COPD becomes troublesome. This finding further underscores the 
need to identify and manage patients with COPD more diligently.
In this study, frequent visitors occupied 73.9% of total COPD patients. We think this proportion will be larger 
than that observed in other countries. In Korea, medical cost is relatively low, then patients can easily visit hospi-
tal. Clinicians should carefully apply the results of this study in their countries, considering these unique charac-
teristics of high prevalence of frequent visitors and the low medical cost in Korea.
The main strength of this study is that that we included almost all patients with COPD in Korea. Considering 
the prevalence rate (10–15%) and diagnosis rate (2–3%) along with the total population in Korea (50 million), the 
159,025 subjects enrolled in this study might cover almost all patients with COPD in Korea25. However, the study 
also has several limitations. First, the operational definition of COPD used in this study might be different from 
the real-world definition of COPD assessed by pulmonary function tests. Second, the study was conducted in 
Korea, where relatively low hospital utilization costs may lead patients with COPD to visit hospital more readily 
and could affect the frequency of outpatient visits and admissions. Third, the cost-effectiveness should be studied. 
Fourth, other variables that could have effects on exacerbation of COPD including current smoking status27 were 
not evaluated because the HIRA data includes only a limited number of variables. Finally, the management pro-
tocol including inhaler training, smoking cessation, and adherence varied according to the institutes.
conclusions
Frequent outpatient visits provide an opportunity for patients with COPD to undergo pulmonary function tests 
more often and to have their inhaler medication adjusted earlier than would be the case if they made infrequent 
outpatient visits. Frequent outpatient visits can reduce the risk of exacerbations requiring admission by 45–60%. 
We recommend that patients with COPD should visit at least three times per year to optimise their prognosis.
Data availability
The datasets generated during the current study are available from the corresponding author on reasonable 
request.
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